WuXi AppTec [SHA: 603259] closed 6 percent higher at CNY104.60 (USD15) in Shanghai today. Its Hong Kong-listed stock [HKG: ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform ...

Investing.com-- Shares of WuXi AppTec (SS: 603259) surged on Tuesday after the Chinese drug research and manufacturing services firm issued a positive profit outlook, signalling strong revenue and ...

WuXi AppTec, one of the largest CROs in China, has just acquired a Shanghai-based preclinical counterpart, HD Biosciences, building further on its core business. Services HD Biosciences provides ...

SHANGHAI, China, October 29, 2025 (EZ Newswire) -- WuXi AppTec, opens new tab, a global contract research, development, and manufacturing organization (CRDMO), recently hosted its 2025 Investor Day, ...

WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceeds back into its Asian manufacturing ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly weighing sales of certain units and facilities. R&D powerhouse WuXi AppTec has ...